New combo offers hope for tough leukemia
NCT ID NCT07541755
First seen Apr 28, 2026 · Last updated Apr 30, 2026 · Updated 1 time
Summary
This study tests a new combination of drugs (PD-1 inhibitor, venetoclax, and chemotherapy) in 40 adults with T-cell leukemia that has come back or not responded to standard treatment. The goal is to see if this approach can improve remission rates and help patients get to a stem cell transplant. The trial is currently active but no longer recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE T LYMPHOBLASTIC LEUKEMIA (T-ALL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
Conditions
Explore the condition pages connected to this study.